本报（chinatimes.net.cn）记者陈岩鹏 北京报道 2025年9月16日下午，北京中关村（大兴）细胞基因治疗产业园，剂泰科技联合创始人兼CEO赖才达博 士站在发布台前，背后的屏幕上跃动着一枚纳米尺度的"火箭"——这正是全球首个AI驱动的纳米药物递 送平台NanoForge的视觉象征。 人类已拥有基因编辑、mRNA编程等强大工具，但如何将这些"修复代码"精准送达体内30万亿个细胞中 的特定病变部位，一直是行业最大痛点。 "这就像在没有GPS的茫茫宇宙中寻找一颗特定的星球。"剂泰科技人工智能创新科学家王恺博士比喻 道。 更艰难的是，当王恺团队开始构建AI模型时，他们面对的是"三无"困境：无现成数据、无迭代算法、无 成熟模型。纳米递送领域缺乏像自然语言处理中"人类语料库"或结构生物学中"蛋白质数据库"那样的基 础资源。 破局之法是"从零造字"。剂泰科技自主研发了分子模拟平台，在计算机中动态组装由上万个分子构成的 纳米球——这如同用数万块柔软积木完成一场瞬息万变的立体拼图。随后，通过微流控技术将实验规模 缩小到极致，一次并行完成上百个实验，形成"干实验设计—湿实验验证"的闭环飞轮。 NanoForge平台 ...

Core Insights - The company, JiTai Technology, has launched the world's first AI nano-delivery platform, NanoForge, which integrates quantum chemistry and molecular dynamics simulations with proprietary high-throughput wet lab and screening platforms [1][2] - NanoForge enables a closed-loop process from molecular generation, property prediction, AI-guided iterative experiments, to lipid formulation design and optimization, continuously expanding the data barriers in nano-delivery through ongoing learning and evolution [1][2] Company Developments - JiTai Technology possesses over 10 million lipid structures and 100,000 data points for model training, achieving targeted delivery of LNPs to eight organs or tissues, including the liver, lungs, and tumors [2] - The company has developed over 10 pipeline projects, resulting in 7 preclinical candidates and is advancing 4 clinical projects, with the fastest pipeline reaching the pre-NDA stage [2] Technological Innovations - The proprietary technology of NanoForge includes the world's largest ionizable lipid library, an innovative AI foundational model for nano-materials, the first nano-delivery AI entity in the industry, and a self-developed integrated wet and dry lab infrastructure [2] - JiTai Technology's co-founder and CEO, Lai Caida, emphasized that NanoForge represents a new paradigm in the industry, showcasing significant efficiency improvements and technological breakthroughs through the integration of large model innovations with iterative wet and dry experiments [2]

OpenCGT平台填补了高端制剂与递送系统产业转化的关键空白。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据 IPO早知道消息， 剂泰科技 日前 完成 4亿元人民币D轮融资 ， 由北京市医药健康产业投资基金 和大兴区产业投资基金联合领投。融资资金将加速剂泰科技多个战略重点的推进，包括平台自动化升 级、自研产品管线推进、深化国际战略合作及高端人才引进。 成立于 2020年的 剂泰科技 作为 一家人工智能（ AI）驱动纳米材料创新的生物科技公司，专注于 利用靶向药物递送和发现技术，帮助生命体战胜疾病和衰老，重获健康和活力 ，现已 成功自主开发 了 AI纳米基座大模型及三大核心解决方案：AiLNP（AI核酸递送系统设计平台）、AiRNA（AI mRNA序列设计平台）、AiTEM（AI小分子制剂设计平台）。 目前， 剂泰科技已具备实现肝脏、肺部、肌肉和免疫细胞等关键组织和细胞的脂质纳米颗粒（ LNP）精准靶向递送能力，在多器官、多组织靶向递送难题上取得突破性进展 ，为肿瘤、代谢系统 疾病、自体免疫性疾病、神经系统退行性疾病等提供成药机会，也在器官水平上为生命体抵抗衰老提 ...

Core Viewpoint - JiTai Technology, a leading AI-driven nanomedicine company, has completed a Series D financing round of 400 million RMB, aimed at accelerating its strategic initiatives in platform automation, product pipeline development, international collaboration, and talent acquisition [2][6]. Financing and Investment - The recent financing round was led by the Beijing Pharmaceutical and Health Industry Investment Fund and the Daxing District Industrial Investment Fund, contributing to a total funding exceeding 2 billion RMB (approximately 300 million USD) since the company's inception [2][6]. - JiTai Technology previously completed two financing rounds in February 2022, raising a total of 150 million USD, and a Series C round in June 2024, raising 100 million USD [5][6]. Company Overview - Founded in 2020, JiTai Technology focuses on AI-driven innovations in nanomaterials, specifically targeting drug delivery and discovery technologies to combat diseases and aging [3]. - The company was co-founded by prominent scientists, including Dr. Chen Hongmin and Dr. Lai Caida, and has developed three core AI platforms: AiLNP, AiRNA, and AiTEM [3]. Industry Position and Collaboration - JiTai Technology is recognized as one of the "Four Little Dragons" in AI pharmaceuticals, alongside Deep Intelligence, Crystal Technology, and InSilico Medicine, emphasizing a collaborative rather than competitive approach within the industry [4]. - The company has achieved breakthroughs in targeted delivery capabilities for key organs and cells, providing opportunities for treating various diseases, including tumors and neurodegenerative disorders [4]. Strategic Initiatives - The company has launched the Open CGT technology platform, which aims to address industry challenges in precise drug delivery and facilitate the development of breakthrough cell and gene therapies [6][7]. - The first project under this platform focuses on enabling Rui Zheng Gene to develop mRNA-LNP-based liver-targeted CRISPR gene editing therapies [7]. Future Outlook - JiTai Technology's CEO highlighted that cell and gene therapy (CGT) will be a pillar of China's biopharmaceutical industry, representing the next generation of drug development [8]. - The company aims to contribute significantly to the entire drug delivery process, facilitating the transition from early-stage pipelines to market-ready products [8].